Marth, Christian
Vergote, Ignace
Scambia, Giovanni
Oberaigner, Willi
Clamp, Andrew
Berger, Regina
Kurzeder, Christian
Colombo, Nicoletta
Vuylsteke, Peter
Lorusso, Domenica
Hall, Marcia
Renard, Vincent
Pignata, Sandro
Kristeleit, Rebecca
Altintas, Sevilay
Rustin, Gordon
Wenham, Robert M.
Mirza, Mansoor Raza
Fong, Peter C.
Oza, Amit
Monk, Bradley J.
Ma, Haijun
Vogl, Florian D.
Bach, Bruce A.
Funding for this research was provided by:
Amgen Inc.
UCH/UCL Biomedical Research Centre
UCL Experimental Cancer Medicine Centre
This article is maintained by: Elsevier
Article Title: ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Journal Title: European Journal of Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ejca.2016.09.004
Content Type: article
Copyright: © 2016 Published by Elsevier Ltd.